News

Levée de fonds de 135 millions USD pour notre client SpliceBio

Patents

$135 million raised for our client SpliceBio

22 July, 2025

Denis Bourgarel and Anna-Lila Kaushik

Founded in September 2012, SpliceBio is a clinical-stage genetic medicine company pioneering protein splicing to treat diseases caused by large gene mutations.

This recent fundraising strengthens SpliceBio's growth and enables it to continue developing innovative products for genetic eye diseases that cause blindness in children and adults.

Our experts Denis Bourgarel, Partner, Life Sciences Patent Practice Group Leader at Plasseraud IP, French & European Patent Attorney, and Anna-Lila Kaushik, French & European Patent Attorney, assist SpliceBio with its IP strategy and patent portfolio.

Congratulations to this innovative company, which has experienced rapid growth since its creation!

For more information: https://splice.bio/splicebio-secures-135-million-series-b-financing-to-advance-lead-program-sb-007-in-stargardt-disease-and-expand-pipeline-of-genetic-medicines/

On the same expertise
By the same author

On the same expertise

Plasseraud IP at Adopt AI – Grand Palais International Summit 2025

20 November, 2025

Jérémie Palacci

Plasseraud IP at Adopt AI – Grand Palais International Summit 2025

On 25 and 26 November 2025, Jeremie Palacci, Partner at Plasseraud IP, will participate in the Adopt AI International Summit organised by Artefact at (...)

Plasseraud IP will take part in MEDICA

13 November, 2025

Atom Tong Xi Jun

Plasseraud IP will take part in MEDICA

The World Forum for Medicine held from November 17 to 20, 2025 in Düsseldorf, Germany. Our partner Atom TONG Xi Jun, European & Chinese Patent (...)

Allergen Alert, a deeptech company specializing in rapid food allergen detection for individuals and professionals, has raised €3.6 million in funding !

12 November, 2025

Denis Bourgarel

Allergen Alert, deeptech spécialisée dans la détection rapide des allergènes alimentaires à destination des particuliers et des professionnels, a annoncé une levée de fonds de 3,6 millions d’euros !

This investment will enable the company to finalize the technical development of its solution and accelerate the industrialization of its production (...)

Plasseraud IP is proud to sponsor the first ever trilateral seminar dedicated to young AIPPI members !

10 November, 2025

Plasseraud IP is proud to sponsor the first ever trilateral seminar dedicated to young AIPPI members !

Jointly organized by the Young Members Committees of AIPPI France, Germany, and Italy, this unique event will take place on November 14, 2025, in (...)

$45 million Series A funding round for our client Genomines

6 November, 2025

Denis Bourgarel

$45 million Series A funding round for our client Genomines

Founded in 2021, Genomines is a deeptech startup that uses biotechnology to reinvent the mining industry. This funding will enable Genomines to (...)

Plasseraud IP welcomes Jérémie Palacci as Partner and strengthens its expertise in Artificial Intelligence and Quantum Computing

5 November, 2025

Jérémie Palacci

Plasseraud IP accueille Jérémie Palacci en tant qu’Associé et renforce son expertise en intelligence artificielle et informatique quantique

Press Release Paris, 4 November 2025 Plasseraud IP welcomes Jérémie Palacci as Partner and strengthens its expertise in Artificial Intelligence and (...)

Plasseraud IP at APAA 2025 in Kuala Lumpur

4 November, 2025

Guylène Kiesel Le Cosquer

Plasseraud IP à l’APAA 2025 à Kuala Lumpur

Our experts, Guylène Kiesel Le Cosquer, Partner and Board Member, and Ina Schreiber, Partner and Head of the Patent Department, represent Plasseraud (...)

Ipsen announces its intention to acquire ImCheck Therapeutics

4 November, 2025

Denis Bourgarel

Ipsen announces its intention to acquire ImCheck Therapeutics

On October 22, 2025, the biopharmaceutical group Ipsen announced that it had entered into a definitive agreement to acquire ImCheck Therapeutics, a (...)

Four Plasseraud IP experts ranked among the best in IAM Global Leaders 2026

29 October, 2025

Quatre experts de Plasseraud IP distingués parmi les meilleurs dans IAM Global Leaders 2026

Plasseraud IP is proud to announce that Cyra Nargolwalla, Bertrand Loisel, Eric Burbaud, and Ina Schreiber have once again been ranked among the best (...)

Plasseraud IP at the Osong Cosmetics & Beauty Expo 2025 in South Korea

27 October, 2025

Park Seowon

Plasseraud IP at the Osong Cosmetics & Beauty Expo 2025 in South Korea

On October 23, 2025, Vincent Girard and Seowon PARK, experts at Plasseraud IP, represented the firm at the conference organized by the FKCCI (French (...)

On the same expertise

Allergen Alert, a deeptech company specializing in rapid food allergen detection for individuals and professionals, has raised €3.6 million in funding !

20 November, 2025

Denis Bourgarel

Allergen Alert, deeptech spécialisée dans la détection rapide des allergènes alimentaires à destination des particuliers et des professionnels, a annoncé une levée de fonds de 3,6 millions d’euros !

This investment will enable the company to finalize the technical development of its solution and accelerate the industrialization of its production (...)

$45 million Series A funding round for our client Genomines

6 November, 2025

Denis Bourgarel

$45 million Series A funding round for our client Genomines

Founded in 2021, Genomines is a deeptech startup that uses biotechnology to reinvent the mining industry. This funding will enable Genomines to (...)

Ipsen announces its intention to acquire ImCheck Therapeutics

5 November, 2025

Denis Bourgarel

Ipsen announces its intention to acquire ImCheck Therapeutics

On October 22, 2025, the biopharmaceutical group Ipsen announced that it had entered into a definitive agreement to acquire ImCheck Therapeutics, a (...)

100 million USD fundraising for our client Oculis!

11 March, 2025

Denis Bourgarel

Levée de fonds de 100 millions USD pour notre client Oculis !

Founded in December 2017, Oculis is an international biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic diseases purposefully (...)

€15 Million Fundraising for our client Faircraft!

20 February, 2025

Charlotte Montaud

Levée de fonds de 15 millions d’euros pour notre client Faircraft !

Founded in 2021 by Haïkel Balti and Cesar Valencia gallardo, Faircraft is a Paris-based start-up specializing in biotechnology. Driven by advances in (...)

Plasseraud IP partner of Lyonbiopôle's 2023 Collaborative Day

17 October, 2023

Denis Bourgarel

Plasseraud IP partenaire de la Journée Collaborative 2023 de Lyonbiopôle

Plasseraud IP is a partner of the 17th Collaborative Day organized by Lyonbiopôle, the competitiveness cluster that brings together public and (...)

European Patent Forum, in Paris on 11 September and Munich on 13 September 2018

14 September, 2018

European Patent Forum, à Paris le 11 septembre et Munich le 13 septembre 2018

As a sponsor of the event organized by Managing Intellectual Property (MIP), Cabinet Plasseraud participated in a panel discussion. Cyra Nargolwalla (...)

On the same expertise

G 1/23 (“Solar Cell”) - New Standard for Prior Art

25 July, 2025

Lilia Leghmizi

On 27 June 2023, in case T 438/19, Technical Board 3.3.03 referred key questions to the Enlarged Board of Appeal about the conditions under which a (...)

T 1580/23 : the sole mention of a telecommunication standard in the description of a European patent is not sufficient to claim an effect relative to the implementation of the standard

17 July, 2025

Bruno Loubet

T 1580/23 : la seule mention d'une norme de télécommunication dans la description d'un brevet européen ne suffit pas à revendiquer un effet relatif à la mise en œuvre de la norme

The decision T 1580/23 of the Boards of Appeal 3.5.05 of the European Patent Office (EPO) is an appeal decision concerning an opposition against the (...)

G 1/24 : Claim Interpretation at the EPO - No Legal Anchor, but a Clear(er?) Path Forward

25 June, 2025

Nadine Rocaboy

G 1/24 Claim Interpretation at the EPO: No Legal Anchor, but a Clear(er?) Path Forward

The Enlarged Board of Appeal’s recent decision in G 1/24 has provided significant clarification regarding the interpretation of claims when assessing (...)

ChatGPT is not a skilled person

28 May, 2025

Louis Lavigne

ChatGPT is not a skilled person

In a recent decision T 1193/23 - 3.2.06 by the Boards of Appeal of the European Patent Office (EPO), the role of artificial intelligence, (...)

“Published after but filed before”: dealing with this kind of prior art - Obtaining an EP Patent - A crash course for the US applicant #8

6 February, 2025

Nadine Rocaboy

“Published after but filed before”: dealing with this kind of prior art - Obtaining an EP Patent - A crash course for the US applicant #8

“Published after but filed before”: dealing with this kind of prior art A patent application having a filing date earlier than the filing date of (...)

Landmark Decision by the Unified Patent Court: Shedding Light on Infringement by Equivalence

3 February, 2025

Nadine Rocaboy

Landmark Decision by the Unified Patent Court: Shedding Light on Infringement by Equivalence

By the end of 2024, the Unified Patent Court (UPC) offered a wonderful gift: the first decision ruling on infringement by equivalence. The decision (...)

Opposition in France: French specificities and initial assessment of oppositions for patents in class "A61" ("Medical or veterinary science; Hygiene").

4 July, 2024

Isabelle Magnin-Feysot

Opposition in France: French specificities and initial assessment of oppositions for patents in class "A61" ("Medical or veterinary science; Hygiene").

1/ General considerations on opposition proceedings in France Opposition proceedings for French patents before the French Patent Office (INPI), are (...)

EP and US patent offices expand their uses of e-signatures

5 April, 2024

Laurence Loumes

EP and US patent offices expand their uses of e-signatures

The EPO and the USPTO have issued recent decisions to expand the use of e-signatures, including the use of commercial solutions such as DocuSign® or (...)

Patent term: how to calculate the expiration date of an EP patent? - Obtaining an EP Patent - A crash course for the US applicant #7

4 April, 2024

Nadine Rocaboy

Obtaining an EP Patent - A crash course for the US applicant #7 - Patent term: how to calculate the expiration date of an EP patent?

Patent term: how to calculate the expiration date of an EP patent? In most patent legislations, the duration of a patent is generally 20 years from (...)

Claim fees: how to avoid their payment? - Obtaining an EP Patent - A crash course for the US applicant #6

5 March, 2024

Nadine Rocaboy

Obtaining an EP Patent - A crash course for the US applicant #6

Claim fees: how to avoid their payment? When filing a patent application, most patent legislations require the payment of claim fees above a certain (...)